1P50CA210964-01A1 (P50) ApplID: 9418217 | |||
---|---|---|---|
Title | Mayo Clinic Hepatobiliary SPORE | ||
Institution | MAYO CLINIC ROCHESTER, ROCHESTER, MN | ||
Principal Investigator | MC NIVEN, MARK | NCI Program Director | Nothwehr |
Cancer Activity | Translation Research (formerly Organ Systems) | Division | DCTD |
Funded Amount | $2,300,000 | Project Dates | 09/10/2018 - 08/31/2023 |
Fiscal Year | 2018 | Project Type | Grant |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Childhood Cancers (23.0%) Digestive Diseases (98.0%) |
Gallbladder (22.0%) Liver Cancer (78.0%) |
||
Research Type | |||
Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications Resources and Infrastructure Related to Treatment and the Prevention of Recurrence Education and Communication Research |
|||
Abstract | |||
OVERALL ? PROJECT SUMMARY The Mayo Clinic Specialized Program of Research Excellence in Hepatobiliary Cancers builds upon four exceptional and diverse translational projects and three well-constructed and responsive cores that, together, promise substantial steps forward. In addition, our proposed Career Enhancement Program and Developmental Research Program are designed with the utmost support. And finally, the Mayo Clinic, the Mayo Clinic Cancer Center, and the SPORE programs, now underway at the institution, stand behind this endeavor and will provide important support toward integrating resources, skilled staff, and leadership guidance to ensure success. This confluence of expertise, resources, structure, and accountability will drive the initial five years of the HBCs SPORE to achieve its intended goals. Our approach is comprehensive and milestone-focused. We look forward to working with NCI leadership, our partners, and our patients to make this program a success." |